Articles tagged with “cross-border-licensing”

Pfizer-Innovent $10.5B Deal & China Licensing Playbook

Examine the $10.5B Pfizer-Innovent collaboration. This analysis covers their 12-drug ADC oncology portfolio and the China cross-border licensing playbook.

35 min read

5/13/2026

pfizer innovent deal oncology licensing antibody drug conjugates cross-border licensing cancer drug development multispecific antibodies pharma partnerships china biotech

Trispecific Antibody HH160: BeOne and Huahui Licensing Deal

Analyze the BeOne-Huahui licensing agreement for the HH160 PD-1/CTLA-4/VEGF trispecific antibody. Review recent China biotech cross-border licensing trends.

40 min read

4/25/2026

trispecific antibodies china biotech licensing hh160 beone medicines huahui health cancer immunotherapy cross-border licensing immuno-oncology